EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Investment analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences ...

Edwards Lifesciences Corp. engages in the patient ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter ...

Edwards Lifesciences stock popped Wednesday on strong ... Transcatheter Aortic Valve Replacement (TAVR) global sales grew 5.3% year-over-year to $1.04 billion in the fourth quarter.

The tricuspid valve is anatomically complex. It’s often called the “forgotten valve” because of its position in the back of ...

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

Gregg Stone cast doubt on its reliability in trials, while David Cohen said QoL matters to patients and should be measured.

During the fourth quarter, the Harbor Capital Appreciation Fund returned 6.22%, underperforming its benchmark, the Russell ...

For the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...